Use of third generation gonadotropin-releasing hormone antagonists in in vitro fertilization-embryo transfer: A review

Obstetrical and Gynecological Survey

Volumn 56, Issue 9, 2001, Pages 576-588

  Elter, Koray ^a   Nelson, Linda R ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; GANIRELIX; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR;

CLINICAL PROTOCOL; DOWN REGULATION; EMBRYO TRANSFER; FERTILIZATION IN VITRO; HUMAN; LUTEAL PHASE; PREGNANCY RATE; REVIEW; SIDE EFFECT;

EID: 0034851792     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-200109000-00024     Document Type: Review

References (56)

1. Gonadotropin-releasing hormone and its analogues
2. Molecular mechanism of gonadotropin releasing hormone action. II. The effector system
3. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone
4. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: An overview
5. Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: Agonists and antagonists
6. Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women
7. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers
8. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers
9. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers
10. Gonadotropin-releasing hormone antagonist: New tools vs. old habits
11. Ovarian stimulation for assisted reproduction with HMG and concomitant mid-cycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: A prospective uncontrolled phase III study
12. Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels
13. Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures
14. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix
15. The ovarian hyperstimulation syndrome
16. The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women
17. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program
18. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in vitro fertilization cycles: A pilot study
19. The use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer: A dose finding study of 3 versus 2 mg
20. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin)
21. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (cetrorelix): A pilot study with minimal stimulation
22. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation
23. Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin-releasing hormone (GnRH)-antagonist cetrorelix at different dosages
24. Subtle progesterone rise after the administration of the gonadotrophin-releasing hormone antagonist cetrorelix in intracytoplasmic sperm injection cycles
25. Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (cetrorelix)
26. Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation
27. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles
28. Ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin
29. Addition of GnRH antagonist in cycles of poor responders undergoing IVF
30. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)
31. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon)
32. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe, and convenient: Results of a controlled, randomized, multicentre trial
33. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation
34. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation
35. Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase
36. Follicular development and early luteal function of conception and non-conceptional cycles after human in-vitro fertilization: Endocrine correlates
37. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation
38. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol
39. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: Results of a prospective randomized trial
40. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist cetrorelix
41. A pilot study involving minimal ovarian stimulation for in vitro fertilization: Extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix
42. Cetrotide confirmatory trial of cetrorelix/0.25 mg in 26 women undergoing ovarian stimulation with recombinant follicle stimulating hormones for IVF, ICSI, and embryo transfer
43. Improved pregnancy outcome with gonadotropin-releasing hormone agonist (GnRH-a) stimulation is due to the improvement in oocyte quantity rather than quality
44. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles
45. Expression of gonadotropin-releasing hormone (GnRH) gene in human uterine endometrial tissue
46. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle
47. Embryo implantation and GnRH antagonists: Embryo implantation: The Rubicon for GnRH antagonists
48. Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, cetrorelix, and GnRH agonists
49. Will GnRH antagonists provide new hope for patients considered "difficult responders" to GnRH agonist protocols?
50. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Certrotide) in controlled ovarian stimulation for assisted reproduction
51. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: Preliminary report: Short communication
52. Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix)
53. Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray
54. The LHRH antagonist cetrorelix: A review
55. Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelix